Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDContineum Therapeutics, Inc. Class A Common Stock Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | -$0.47 | -$0.47 | -$0.47 |
| Q2 2025 | 1 | -$0.51 | -$0.51 | -$0.51 |
| Q3 2025 | 1 | -$0.67 | -$0.67 | -$0.67 |
Contineum Therapeutics, Inc. Class A Common Stock Earnings Date And Information
Contineum Therapeutics, Inc. Class A Common Stock last posted its earnings results on Wednesday, November 6th, 2024. The company reported $-0.4 earnings per share for the quarter, topping analysts' consensus estimates of $-0.41 by $0.01. The company had revenue of 0 for the quarter and had revenue of 50.00 M for the year. Contineum Therapeutics, Inc. Class A Common Stock has generated $1 earnings per share over the last year ($1.28 diluted earnings per share) and currently has a price-to-earnings ratio of -10.47. Contineum Therapeutics, Inc. Class A Common Stock has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
Contineum Therapeutics, Inc. Class A Common Stock Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2024 | Q3 2024 | -$0.41 | -$0.40 | 0.01 | $0 | $0 |
| 08/14/2024 | Q2 2024 | -$0.35 | $0 | $0 | ||
| 05/16/2024 | Q1 2024 | -$0.46 | -$0.33 | 0.13 | $0 | |
| 12/30/2023 | Q4 2023 | -$0.31 | $0 | |||
| 09/29/2023 | Q3 2023 | -$0.25 | $0 | |||
| 06/29/2023 | Q2 2023 | $1.62 | $50.00 M | |||
| 03/30/2023 | Q1 2023 | -$0.19 | $0 | |||
| 12/30/2022 | Q4 2022 | -$0.30 | $0 |
Contineum Therapeutics, Inc. Class A Common Stock Earnings: FAQ's
When is Contineum Therapeutics, Inc. Class A Common Stock's earnings date?
Contineum Therapeutics, Inc. Class A Common Stock has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates.
Did Contineum Therapeutics, Inc. Class A Common Stock beat their earnings estimates last
quarter?
In the previous quarter, Contineum Therapeutics, Inc. Class A Common Stock (:CTNM) reported $-0.4 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.41 by $0.01.
How can I listen to Contineum Therapeutics, Inc. Class A Common Stock's earnings conference
call?
The conference call for Contineum Therapeutics, Inc. Class A Common Stock's latest earnings report can be listened to online.
How can I read Contineum Therapeutics, Inc. Class A Common Stock's conference call transcript?
The conference call transcript for Contineum Therapeutics, Inc. Class A Common Stock's latest earnings report can be read online.
How much revenue does Contineum Therapeutics, Inc. Class A Common Stock generate each year?
Contineum Therapeutics, Inc. Class A Common Stock (:CTNM) has a recorded annual revenue of $50.00 M.
How much profit does Contineum Therapeutics, Inc. Class A Common Stock generate each year?
Contineum Therapeutics, Inc. Class A Common Stock (:CTNM) has a recorded net income of $50.00 M. Contineum Therapeutics, Inc. Class A Common Stock has generated $1.36 earnings per share over the last four quarters.
What is Contineum Therapeutics, Inc. Class A Common Stock's price-to-earnings ratio?
Contineum Therapeutics, Inc. Class A Common Stock (:CTNM) has a price-to-earnings ratio of -10.47 and price/earnings-to-growth ratio is 0.87.